The purpose of the study is to find out whether the medication is safe and can be tolerated without serious side effects when used for an extended time. Participants will take the tablet daily and attend regular visits where simple checks are done, including blood or urine checks (lab test), a heart test that records electrical activity (ECG), and measurements of blood pressure and heart rate (vital signs) to see how the body is responding.

Throughout the study, any side effects, changes in the test results, and any serious health problems will be recorded and compared with the information collected at the start of the study. The trial is open‑label, meaning that both the researchers and participants know the medication being taken.

Participants will receive three treatment cycles of the infusion over a short period, followed by regular check‑ups to monitor health and any side effects. Researchers will watch for cancer returning, using a set of rules called RECIST 1.1 that define how to measure changes in tumor size on scans. Terms such as recurrence (cancer returning), progression (cancer getting larger or spreading), and pneumonitis (inflammation of the lung tissue) are explained in plain language during visits. Additional observations include overall survival (how long a person lives after starting treatment) and the occurrence of any serious side effects. The study continues with follow‑up visits for several months after the last infusion to gather the needed information.

The study compares two treatment approaches. One group receives a new drug identified as BV100 together with a low dose of polymyxin B, both given through an IV line. The other group receives the older antibiotic colistin combined with a higher dose of ampicillin/sulbactam, also by IV infusion. The purpose of the trial is to determine which combination works better and is safer for patients with this resistant infection. Participants are randomly assigned to one of the two groups, receive the medication for several days, and are then followed for about a month to see how they recover and to monitor any side effects.

The purpose of the trial is to see which of these treatments most effectively clears the bacteria from the lungs, a result known as microbiological eradication. Participants are randomly assigned to receive one of the three options for a short treatment period, then they return for regular check‑ups where sputum samples are collected and health questionnaires are completed to monitor safety, symptom changes, and overall well‑being.

Follow‑up continues for several months after the medication stops, allowing researchers to observe whether the infection stays cleared, how often lung flare‑ups occur, and any side effects that may appear. The information gathered will help determine the best approach to manage this bacterial infection in people with bronchiectasis.

The main goal of the study is to see whether a single dose of the medicine is safe and whether it can raise protein levels to a normal range, with some participants receiving a second dose later to assess longer‑term effects. Participants will receive the infusion, then attend regular visits over several months during which blood samples and simple health checks are performed.

Researchers will watch for any side effects, measure the amount of the protective protein in the blood, and test how well it works using a laboratory test called a elastase inhibition assay. They will also check lung function and liver health through routine exams and questionnaires to understand how the treatment impacts overall well‑being.

The purpose of the study is to find out whether the new medicine can improve breathing and reduce serious flare‑ups compared with the placebo. People who join will be randomly assigned to one of the two groups, and neither the participants nor the study staff will know which treatment each person receives (double‑blind). Over several months, participants will come to the clinic for routine visits where their lung function, symptoms and overall health will be checked.

During the study, participants will receive the injections at set intervals and will have simple breathing tests, such as measuring forced expiratory volume in one second (FEV1), which shows how much air can be exhaled quickly. They will also answer short questionnaires about how they feel, and will have basic safety checks like blood tests and a quick heart rhythm check (ECG). All of this information helps researchers see if the medicine works and is safe.

During the study, participants will be assigned to receive either depemokimab or a placebo through a subcutaneous injection, which is a shot given just under the skin. The study is designed so that neither the participants nor the researchers know which treatment is being administered. This approach helps ensure that the results are as accurate as possible.

The purpose of the study is to evaluate the safety and feasibility of gradually extending the dosing interval of these biologic therapies over roughly one year. Participants will receive one of the listed medicines at the regular interval used in routine care, and the interval may be lengthened step by step according to a predefined plan. Throughout the study, individuals will attend regular clinic visits where health status, breathing tests, blood samples, and questionnaire responses are collected.

Safety is monitored by checking for any worsening of symptoms, called an exacerbation, which means a sudden increase in asthma problems lasting more than two days. Blood tests look at the number of eosinophils, a type of white blood cell involved in inflammation, and at the level of exhaled nitric oxide (FeNO), a breath test that reflects airway inflammation. Lung function is measured with the amount of air expelled in the first second (FEV1) and the total amount expelled (FVC). Participants also complete the Asthma Control Questionnaire (ACQ) to rate how well their asthma is controlled, and a lab test called polymerase chain reaction (PCR) may be used to detect viruses during any worsening episodes.

Participants in the study will receive either dexpramipexole, a placebo, or other medications such as Budesonide/Formoterol and Ventolin, which are commonly used to manage asthma symptoms. Budesonide/Formoterol is an inhalation powder that helps to reduce inflammation and open the airways, while Ventolin, which contains Salbutamol sulfate, is a pressurized inhalation suspension that helps to quickly relieve asthma symptoms by relaxing the muscles in the airways.

The study will last for one year, during which participants will take the assigned medication and attend regular visits to monitor their asthma symptoms and overall health. The goal is to determine if dexpramipexole can effectively reduce the number of severe asthma attacks and improve the quality of life for those with severe eosinophilic asthma. Participants will be closely monitored to ensure their safety and to assess the effectiveness of the treatment.